Effects of thymoquinone and etoposide combination on cell viability and genotoxicity in human cervical cancer hela cells
Abstract
Methods: Cytotoxicity was evaluated by MTT assay and genotoxicity was determined by Comet assay.
Results: The IC50 values of thymoquinone were 233.6 μM and 145.5 μM, and the IC50 values of etoposide were 167.3 μM and 52.7 μM for 24 and 48 h, respectively. Thymoquinone significantly decreased the approximate IC50 value of etoposide in doses of 15.63 μM and above for 24 h and 31.5 μM and above for 48 h in a dose-dependent manner. 0.1-5 μM thymoquinone and 1 μM etoposide alone did not cause DNA damage, but at higher doses increased DNA damage significantly in a dose-dependent manner. Thymo- quinone significantly reduced DNA damage induced by 10 μM etoposide at the doses of 0.1-10 μM.
Conclusion: Our results show that thymoquinone might increase the cytotoxic and genotoxic effects of etoposide in HeLa cells at high doses and reduce DNA damage at low doses that are not cytotoxic, which suggests that etoposide may increase its anticancer effect at high doses, but comprehensive studies are needed on this subject. This study is a preliminary study and will contribute to the development of new treatment strategies.
Keywords
Supporting Institution
Project Number
References
- Al-Shdefat, R. I., Abd-ElAziz, M. A., & Al-Saikhan, F. I. (2014). Geno- protective and Genotoxic Effects of Thymoquinone on Doxoru- bicin-Induced Damage in Isolated Human Leukocytes. Tropical Journal of Pharmaceutical Research, 13 (12), 2015-2020.
- Ashley, R. E. & Osheroff, N. (2014). Natural products as topoisom- erase II poisons: effects of thymoquinone on DNA cleavage medi- ated by human topoisomerase IIα. Chemical Research in Toxicol- ogy, 27(5), 787-93.
- Attoub, S., Sperandio, O., Raza, H., Arafat, K., Al-Salam, S., Al Sultan, M. A., ..., Adem, A. (2013). Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo. Fundamental & Clinical Pharma- cology, 27(5), 557-69.
- Bashmail, H. A., Aliaa, A.A., Abdulwahab, N., Gehan, A. H., Ghada, A., Hani, C., & Ahmed, M. A. (2018). Thymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apop- totic and autophagic activities. Scientific Reports, 8, 11674.
- Becit, M., & Aydın Dilsiz, S. (2020). An In Vitro Study on the Inter- actions of Pycnogenol® with Cisplatin in Human Cervical Cancer Cells. Turkish Journal of Pharmaceutical Sciences, 17(1), 1-6.
- Collins, A. R., Dobson, V. L., Dusinka, M., Kennedy, G., & Stetina, R. (1997). The comet assay: what can it really tell us? Mutation Re- search, 375, 183-93.
- Coutts, A. S., & La Thangue, N., (2006). The p53 response during DNA damage: impact of transcriptional cofactors. Biochemical Society Symposia, 6, 181–189.
- Dirican, A., Atmaca, H., Bozkurt, E., Erten, C., Karaca, B., & Uslu, R. (2015). Novel combination of docetaxel and thymoquinone in-duces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K–AKT pathway. Clinical and Translational Oncology, 17(2), 145-151.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Authors
Aydan Çağlayan
0000-0002-8534-4878
Türkiye
Publication Date
December 30, 2022
Submission Date
April 20, 2022
Acceptance Date
August 15, 2022
Published in Issue
Year 2022 Volume: 52 Number: 3